

Vaccine-Derived Polioviruses Not Detected by Global Surveillance Screening Assay

Deepa K. Sharma, Uma P. Nalavade, Swapnil Y. Varose, Jagadish M. Deshpande

Author affiliation: Enterovirus Research Centre, Mumbai, India

DOI: <http://dx.doi.org/10.3201/eid2100.150702>

To the Editor: The Global Polio Laboratory Network (GPLN) and the World Health Organization's Polio Eradication Initiative (GPEI) accord high priority to detecting all vaccine-derived polioviruses (VDPVs) because they are neurovirulent and have the potential to cause outbreaks of poliomyelitis and establish poliovirus circulation. In patients with immunodeficiency diseases, persistent infections may become established with live oral poliovirus vaccine (OPV) and develop into VDPVs (1). Laboratories of the GPLN use standard procedures for virus isolation, identification, and intratypic differentiation (2). The real-time reverse transcription PCR (rRT-PCR) VDPV screening assay became available to the GPLN in 2009. Poliovirus isolates that do not become amplified in the VDPV assay are subjected to complete sequencing of viral protein (VP) 1. VDPVs are isolates of Sabin OPV origin that have incorporated ≥ 6 nucleotide substitutions (Sabin2) or ≥ 10 nucleotide substitutions (Sabin1 and Sabin3) in the VP1 region. The VDPV assays were found to be 100% specific for all 3 poliovirus types, 100% sensitive for Sabin1 and Sabin3, and 76% sensitive for Sabin2 (3). Among all cases of circulating VDPV infection reported globally from 2000 to 2013, 10.95%, 97.1%, and 1.8% of cases were caused by types 1, 2, and 3, respectively (4).

To mitigate the risk for infection with VDPV type 2, GPEI envisions a simultaneous global switch from trivalent OPV to bivalent OPV (Sabin1 and Sabin3)—that is, withdrawal of Sabin2—beginning in April 2016 (5). Any type 2 poliovirus detected thereafter will need characterization. Here we report VDPV isolates that escaped detection by the VDPV screening assay used in the GPLN.

Type 3 VDPV was identified in a 1.2-year-old girl with onset of acute flaccid paralysis (AFP) on January 2008. Sabin3 was isolated from stool sample 1 (R46064), collected 11 days after onset of paralysis. Stool sample 2, collected on the 13th day after paralysis, was negative for virus. R46064 was reported as "Sabin-like" by the intratypic differentiation tests (ELISA and conventional RT-PCR) used in the GPLN in 2008 (6,7). The patient had residual weakness compatible with paralytic poliomyelitis; therefore, the isolate was characterized in detail. Complete genome sequence of R46064 showed that the major attenuation sites

reverted to wild type at nt 472 (U→C) in the 5' untranslated region (UTR) and nt 2034 in VP3 (U→C). The capsid region contained 18 nt substitutions, of which 12 were in the VP1 region (online Technical Appendix Table, <http://wwwnc.cdc.gov/EID/article/21/10/15-0702-Techapp1.pdf>). Seven amino acid changes occurred, including 2 at the antigenic site NAg1 (online Technical Appendix Figure 1). The isolate was a recombinant with species C enterovirus in the noncapsid region. R46064 was a VDPV3 isolate by definition. Investigations showed that VDPV3 was not a part of any outbreak.

R46064 produced Sabin3-like results in the VDPV screening assay. R46064 gave false-negative test results because the isolate had a Sabin3 vaccine sequence in the regions corresponding to the probe and primers of the VDPV assay (online Technical Appendix Figure 2).

Type 2 VDPV was found in an immunocompetent girl, 3.5 years of age, in March 2014. Sabin2 was isolated from 2 stool samples collected 5 and 8 days after onset of AFP. Sabin2, isolated from stool sample 1 (R93150), was amplified in the VDPV screening assay (reported as Sabin2-like); the isolate from stool sample 2 (R93152) failed to become amplified (reported for sequencing).

VP1 sequencing of R93152 showed 6 nt substitutions; therefore, it was reported as VDPV2. R93150 was also sequenced to find out whether it contained the Sabin2 homotypic mixture. VP1 sequence of R93150 showed 6 nt substitutions and no evidence of mixed bases. Substitution was not found at VP1 nt 427/428, the main target of the VDPV screening assay.

Complete genome sequence analysis revealed that both isolates contained reversion of the major attenuating site at nt 481 in the 5' UTR. The genomes of both isolates showed no recombination. Both isolates showed 15 nt substitutions in the capsid region, when compared with Sabin2 (online Technical Appendix Table); only 5 substitutions were common to both isolates. R93150 had 4 aa changes; 1 change was at the antigenic site NAg2. R93152 showed 6 aa changes; 2 changes were at NAg3a and NAg3b (online Technical Appendix Figure 1). Thus, VDPVs of 2 distinct VDPV2 lineages were excreted by the patient; 1 isolate was identified as VDPV2, but the other was missed. Although the patient was identified as having VDPV2 infection by the current algorithm, if special interest had not been taken to characterize both isolates, we would not have detected the VDPV2 that produced false-negative results in the screening assay.

The occurrence of VDPV2 and VDPV3 as described above may be rare. However, GPLN laboratories are unlikely to detect VDPV strains that produce false-negative results in the VDPV screening assay. False negatives are of greatest concern to the GPEI because they could impede timely detection of VDPV infections (3,8). Our results

point out the need for reporting and inventorying VDPVs that give a false-negative reaction in the screening assay. This action would help clarify how to further refine the screening assays.

Acknowledgments

We thank Mark Pallansch for providing primers for complete genome sequencing.

The virus strains reported here were identified from isolates submitted by National Polio Laboratory in Lucknow and Ahmedabad, India. AFP surveillance is supported by the World Health Organization, National Polio Surveillance Project.

References

1. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. *Annu Rev Microbiol.* 2005; 59:587–635. <http://dx.doi.org/10.1146/annurev.micro.58.030603.123625>
2. World Health Organization. Supplement to the WHO polio laboratory manual. An alternative test algorithm for poliovirus isolation and characterization. 2004;4(Suppl 1) [cited 2015 Jul 23]. http://apps.who.int/immunization_monitoring/Supplement_polio_lab_manual.pdf
3. Kilpatrick DR, Ching K, Iber J, Chen Q, Yang SJ, De L, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. *J Virol Methods.* 2014;197:25–8. <http://dx.doi.org/10.1016/j.jviromet.2013.11.017>
4. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. *J Infect Dis.* 2014;210:S283–93. <http://dx.doi.org/10.1093/infdis/jiu295>
5. Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2013–2018) [cited 2015 Jul 23]. http://www.polioeradication.org/portals/0/document/resources/strategywork/endgamestratplan_20130414_eng.pdf
6. Glikmann G, Moynihan M, Petersen I, Vestergaard BF. Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type 1. *Dev Biol Stand.* 1983;55:199–208.
7. Kilpatrick DR, Nottay B, Yang CF, Yang SJ, Mulders MN, Holloway BP, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. *J Clin Microbiol.* 1996;34:2990–6.
8. Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. *J Infect Dis.* 2011;203:898–909. <http://dx.doi.org/10.1093/infdis/jiq140>

Address for correspondence: Deepa K. Sharma, Enterovirus Research Centre, Haffkine Institute Compound, AD Marg, Parel, Mumbai-400012, India; email: dsharmad11@gmail.com

Association of Necrotizing Wounds Colonized by Maggots with *Ignatzschineria*-Associated Septicemia

Cécile Le Brun, Martin Gombert, Sylvie Robert, Emmanuelle Mercier, Philippe Lanotte

Author affiliations: Centre Hospitalier Régional Universitaire de Tours, Tours, France (C. Le Brun, M. Gombert, S. Robert, E. Mercier, P. Lanotte); Université François Rabelais de Tours, Tours (S. Robert, P. Lanotte); Institut National de la Recherche Agronomique, Nouzilly, France (S. Robert, P. Lanotte)

DOI: <http://dx.doi.org/10.3201/eid2110.150748>

To the Editor: *Ignatzschineria* is a recently described genus of bacteria that have been rarely implicated in human disease (1–3). We report a patient in France with septicemia caused by *I. ureiclastica*.

In October 2013, a 69-year-old man was found unconscious in a forest close to Tours in the Loire Valley, France. The patient had hypotension with auricular fibrillation complicated by cardiorespiratory arrest and was admitted to the general intensive care unit of Tours University Hospital. He also had cyanosis of the extremities, a necrotic skin lesion on the right shoulder, and a large number of maggots around the genital organs. Empiric treatment with ceftriaxone was initiated. Blood cultures on admission revealed several microbes: *Enterococcus faecalis*, *Enterobacter cloacae*, *Providencia stuartii*, *Corynebacterium* spp., and a gram-negative bacillus resembling *Pseudomonas*. This bacillus was sensitive to all β -lactams, aminoglycosides, fluoroquinolones, colistin, and trimethoprim/sulfamethoxazole but was resistant to fosfomycin. Ten days after admission to the hospital, the patient was found dead in his bed from no evident cause, despite recent improvement of his clinical state. No autopsy was conducted.

The unidentified gram-negative bacillus was an oxidase-positive strict aerobe. The 16S rRNA and *gyrB* genes were amplified and sequenced (4,5). The 897-bp 16S rRNA sequence obtained for the bacterium was 99% identical to sequences from *I. larvae* type strain L1/68T (GenBank accession no. AJ252143) and *I. ureiclastica* type strain FFA3T (GenBank accession no. EU008089). The 973-bp *gyrB* sequence of the isolate was 96% similar to the sequence of *I. ureiclastica* type strain FFA3T (GenBank accession no. FJ966120) and 92% with *I. larvae* type strain L1/68T (GenBank accession no. FJ966121). The 16S rRNA and *gyrB* sequences (GenBank accession nos. KR184134 and KR184135) were compared with

Vaccine-Derived Polioviruses Not Detected by Global Surveillance Screening Assay

Technical Appendix

Technical Appendix Table. Nucleotide substitutions in 5' UTR and capsid region of type 2 and type 3 VDPV strains*

Region	Type 2 VDPV			Type 3 VDPV	
	Nucleotide no.	R93150	R93152	Nucleotide no.	R46064
5'UTR	481	A→G	A→G	472	T→C
	681		T→C		
	707	A→T			
	730		T→C		
VP4	831	T→C		844	A→G
	927		C→A		
VP2	1059	C→T	C→T	1066 1567	T→C T→C
	1164	T→G			
	1168		C→T		
	1469	A→G			
	1507	C→T			
	1704	G→A			
VP3	1857		C→T	2034 2278 2401	T→C T→C T→C
	1943		G→T		
	2025		G→A		
	2046	C→T			
	2055	A→G	A→G		
	2420	A→G	A→G		
	2475		G→A		
	VP1	2490	T→C		
2525		A→G			
2739		C→T			
2766			T→C		
2829		T→C			
2908			A→G		
2958		T→C			
2992		A→G	A→G		
3057			A→G		
3381			T→G		

*Nucleotide substitutions are shown as Sabin→Isolate; Nucleotide substitutions causing amino acid changes are shown in bold type; The complete genome sequences of R93150, R93152, and R46064 were submitted to GenBank (accession nos. KR259356–KR259358). UTR, untranslated region; VDPV, vaccine-derived poliovirus.

	VP2			VP3		VP1		
	NAg3b	NAg2	NAg2	NAg3a	NAg3b	NAg1	NAg2	NAg3a
	71	164	268	54	75	88	222	287
Sabin 2	WRK	TNATNPARNPRT	PRTQ	PLNLTSQRVELSD	TAHSDT	AIIEVDNDAPTKRASRLFS	STEGD	KDGLT
R93150 S
R93152	. C I
Sabin 3	WGK	NAVTSFKREPKE	PKFQ	PLNLESTKVTLSD	SADLSQ	IEVDNEQPTTRAQKLFAMW	QIGDS	NNLDP
R46064 Q.I

Technical Appendix Figure 1. Amino acid changes at neutralizing antigenic sites (NAg) of VDPVs. The number indicates the first amino acid position within the antigenic site.

```

Sabin2      AAACTGGAATTTTTACATATTCGAGATTTGACATGGAGTTCACTTTTGTGGTCACCTCA
R-93150    AAACTGGAATTTTTACATATTCGAGATTTGACATGGAGTTCACTTTTGTGGTCACCTCA
R-93152    AAACTGGAATTTTTACATATTCGAGATTTGACATGGAGTTCACTTTTGTGGTCACCTCA
*****

Sabin2      AACTACATTGATGCAAATAACGGACATGCATTGAACCAAGTTTATCAGATAATGTATATA
R-93150    AACTACATTGATGCAAATAACGGACATGCATTGAACCAAGTTTATCAGATAATGTACATA
R-93152    AACTACGTTGATGCAAATAACGGACATGCATTGAACCAAGTTTATCAGATAATGTATATA
*****

Sabin2      CCACCCGGAGCACCTATCCCTGGTAAATGGAAATGACTATACGTGGCAGACGTCTCTAAC
R-93150    CCACCCGGAGCACCTATCCCTGGTAAATGGGATGACTATACGTGGCAGACGTCTCTAAC
R-93152    CCACCCGGAGCACCTATCCCTGGTAAATGGGATGACTATACGTGGCAGACGTCTCTAAC
*****

Sabin3      GTTCGTGTTGTCAATGATCACAACCCCACTAAAGTAACCTCCAAAGTCCGCATTTACATG
R-46064    GTTCGTGTTGTCAATGATCACAACCCCACTAAAGTAACCTCCAAAGTCCGCATTTACATG
*****

Sabin3      AAACCCAAACACGTACGTGTCTGGTGCCCTAGACCGCCGCGCGGGTACCTTATTATGGA
R-46064    AAACCCAAACACGTACGTGTCTGGTGCCCTAGACCGCCGCGCGGGTACCTTATTATGGA
*****

Sabin3      CCAGGGGTGGACTATAGGAACAACTTGGACCCCTTATCTGAGAAAGGTTTGACCACATAT
R-46064    CCAGGGGTGGACTATAGGAACAACTTGGACCCCTTATCTGAGAAAGGTTTGACCACATAT
*****

```

Technical Appendix Figure 2. Nucleotide sequence alignment of VDPV2 and VDPV3 with corresponding Sabin vaccine virus sequences. Primer and probe regions are shown in bold type.